Candorium Free Members
Join Candorium to access the full article and more
Free Member Benefits:
✔
Comment & Reply✔
Newsletter Access✔
Follow Authors✔
Share via SMS Go Back
Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022
By AP News - Nov 03, 2022, 08:06 PM ET
Last Updated - Jun 23, 2023, 07:53 PM EDT
Conference call and webcast to be held at 4:30 p.m. EDT
NEW HAVEN, Conn., Nov. 3, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of serious chronic cough conditions, today announced that management will host a conference call and live audio webcast on Thursday, November 10, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2022.
To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 4950734. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER) for the treatment of serious chronic cough conditions. The Company has successfully completed a Phase 2 trial of Haduvio for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF). Based on this positive data, Trevi plans to focus future clinical development on chronic cough conditions, including IPF, refractory chronic cough, and interstitial lung diseases (ILDs).
For more information, visit www.TreviTherapeutics.com and follow the company on Twitter and LinkedIn.
About Haduvio
Haduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are centrally and peripherally active and known to be critical mediators of cough and itch. Nalbuphine's mechanism of action may also mitigate the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Parenteral nalbuphine is not currently scheduled as a controlled substance by the DEA in the United States or by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q3-2022-financial-results-and-provide-a-corporate-update-on-november-10-2022-301668183.html
SOURCE Trevi Therapeutics, Inc.
Sponsored
Read More from Business
Popular News
Latest News
